BioAcyl Corp
BioAcyl Corp |
|
 |
 |
 |
|
Kou, L., Jiang, X., Huang, H., Lin, X., Zhang, Y., & Yao, Q., et al. (2020). The role of transporters in cancer redox homeostasis and cross-talk with nanomedicines. Asian Journal of Pharmaceutical Sciences, 15(2), 145–157. Added by: Dr. Enrique Feoli (11/10/2020, 19:10) Last edited by: Dr. Enrique Feoli (11/10/2020, 19:10) |
 |
| Resource type: Journal Article DOI: 10.1016/j.ajps.2020.02.001 ID no. (ISBN etc.): 1818-0876 BibTeX citation key: Kou2020 View all bibliographic details  |
Categories: BioAcyl Corp Subcategories: Redox microenvironment Creators: Chen, Huang, Jiang, Kou, Lin, Yao, Zhang Collection: Asian Journal of Pharmaceutical Sciences |
Views: 2/237
|
| Abstract |
|
Tumor cell usually exhibits high levels of reactive oxygen species and adaptive antioxidant system due to the metabolic, genetic, and microenvironment-associated alterations. The altered redox homeostasis can promote tumor progression, development, and treatment resistance. Several membrane transporters are involved in the resetting redox homeostasis and play important roles in tumor progression. Therefore, targeting the involved transporters to disrupt the altered redox balance emerges as a viable strategy for cancer therapy. In addition, nanomedicines have drawn much attention in the past decades. Using nanomedicines to target or reset the redox homeostasis alone or combined with other therapies has brought convincing data in cancer treatment. In this review, we will introduce the altered redox balance in cancer metabolism and involved transporters, and highlight the recent advancements of redox-modulating nanomedicines for cancer treatment. Graphical abstract Tumor cells exhibits high levels of reactive oxygen species and adaptive antioxidant system, beneficial to tumor progression, development, and treatment resistance. Nanomedicine targeting to disrupt the adaptive redox balance emerges as a viable strategy for cancer therapy.
|